Log In
BCIQ
Print this Print this
 

Soriatane, acitretin

  Manage Alerts
Collapse Summary General Information
Company GlaxoSmithKline plc
DescriptionOral retinoid
Molecular Target Unknown
Mechanism of Action 
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentMarketed
Standard IndicationPsoriasis
Indication DetailsTreat moderate to severe plaque psoriasis
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$3,600.0M

$2,900.0M

$300.0M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

08/03/2009

$3,600.0M

$2,900.0M

$300.0M

Get a free BioCentury trial today